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Background: Mobile elements are active in the human genome, both in the germline and cancers, where they can
mutate driver genes.
Results: While analysing whole genome paired-end sequencing of oesophageal adenocarcinomas to find genomic
rearrangements, we identified three ways in which new mobile element insertions appear in the data, resembling
translocation or insertion junctions: inserts where unique sequence has been transduced by an L1 (Long interspersed
element 1) mobile element; novel inserts that are confidently, but often incorrectly, mapped by alignment software to
L1s or polyA tracts in the reference sequence; and a combination of these two ways, where different sequences within
one insert are mapped to different loci. We identified nine unique sequences that were transduced by neighbouring
L1s, both L1s in the reference genome and L1s not present in the reference. Many of the resulting inserts were small
fragments that include little or no recognisable mobile element sequence. We found 6 loci in the reference genome to
which sequence reads from inserts were frequently mapped, probably erroneously, by alignment software: these were
either L1 sequence or particularly long polyA runs. Inserts identified from such apparent rearrangement junctions
averaged 16 inserts/tumour, range 0–153 insertions in 43 tumours. However, many inserts would not be detected by
mapping the sequences to the reference genome, because they do not include sufficient mappable sequence. To
estimate total somatic inserts we searched for polyA sequences that were not present in the matched normal or other
normals from the same tumour batch, and were not associated with known polymorphisms. Samples of these candidate
inserts were verified by sequencing across them or manual inspection of surrounding reads: at least 85 % were somatic
and resembled L1-mediated events, most including L1Hs sequence. Approximately 100 such inserts were detected per
tumour on average (range zero to approximately 700).
Conclusions: Somatic mobile elements insertions are abundant in these tumours, with over 75 % of cases having a
number of novel inserts detected. The inserts create a variety of problems for the interpretation of paired-end
sequencing data.
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Mobile elements are elements in the genome that can
move, either by excision and re-insertion of the DNA it-
self or by insertion of copies made by reverse transcrip-
tion of an mRNA intermediate [1–3]. The most active in
humans are the non-retrovirus-like retrotransposons,
the LINE and SINE elements, including respectively L1s
and Alus. Intact, active L1s are transcribed into mRNA,
which has two open reading frames. The encoded enzyme
activities include an endonuclease and reverse transcriptase.b
c
d
e
Fig. 1 Inserts produced by L1 activity and how they are treated by paired-
transduction (not to scale). mRNA (orange) is transcribed from an L1 in the
nicked, and the end at the nick used to prime reverse transcription of the
line). cDNA is subsequently integrated, flanked by a short duplication of th
priming in the opposite direction [19]. a, simple L1 insert; b, Transduction o
the L1 polyA addition site (asterisk) into 3’ unique sequence (red) until a po
insert includes a variable amount of the unique sequence and upstream L1
and resulting paired-end sequence reads. Reverse transcription of the mob
These may or may not have any L1 sequence, and the most-truncated inse
are shown in black solid lines if the aligner can map (align) them uniquely
junctions (Fig. 2). Many read pairs will not align (dashed lines) either becau
reference (fine dots). Yellow boxes are target site duplications. d Example of a
may be mapped as a translocation junction. The parent L1 may have a uniqu
consensus, that identifies reads uniquely and maps them to its parent L1. Oth
has a polyA tail, e.g. the ‘element’ on chromosome 15 in Table 1. In some cas
not in general from the element the read is mapped to. e Apparent junction
be aligned to two different loci, appearing to report a rearrangement junction
pair contains polyA and is mapped to one of the polyA runs in the referenceThe endonuclease cuts the genome at a consensus target
site, exposing an end that is used to prime reverse tran-
scription of the L1 mRNA, and the resulting cDNA is in-
tegrated (Fig. 1A). Alus and SVAs do not encode the
necessary enzymes and can only be copied when enzymes
are provided by an intact L1 [4]. Other mRNAs can also
be inserted by L1 enzymes to give novel processed
pseudogenes [5]. In humans, a number of L1 elements
are intact and active, and create novel insertions: in the
germline—causing polymorphism and constitutionalend sequencing. a, b Generation of inserts showing truncation and
germline (or from a newly inserted L1, if complete). Target site is
mRNA to cDNA (green and red), which is often incomplete (dotted
e target site. Some inserts have 5’ inversions, perhaps due to additional
f 3’ unique sequence. Transcription of an L1 sometimes reads through
lyA addition site (asterisk) is encountered. The resulting cDNA and
sequence. c Examples of inserts with transduced unique sequence,
ile element RNA is often incomplete, resulting in 5’ -truncated inserts.
rts may contain little more than polyA. Examples of possible read pairs
to the reference genome; these will usually appear to be translocation
se one read falls in a repeat, or the sequence is not present in the
n insert of an L1 that does not transduce 3’ sequence but nevertheless
e sequence difference, e.g. a single base pair deviation (T > A) from the
er reads (red) are aligned to an L1 (or Alu) in the reference sequence that
es the alignment may be generated by the polyA alone. Such inserts are
that is not even a junction. Occasionally a read pair within an insert may
. For example, one read may map to a transduced sequence, while its
genome
Fig. 2 Mobile element inserts mimic multiple translocations. Circos
plot of mobile element inserts detected by discordant read pairs in
tumour 7409, which had the highest number detected. The genome
is displayed as a circle, chromosomes 1 to Y, with curved lines
representing the apparent rearrangements detected. For example,
the many apparent junctions between chromosome 14 and other
chromosomes (green), represent copies of a chromosome 14 sequence
that have been transduced and inserted all over the genome
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also in non-cancerous somatic tissues (e.g. [4, 15]). Al-
though there are limited data so far, there is an expect-
ation that mobile element insertions will contribute to
mutation of driver genes in cancers.
Two important features of L1 retrotransposition are
truncation and transduction (Fig. 1) [3]. The inserted
copies are often 5’ truncated; and inserts often include
sequence from downstream of the L1 element proper,
because transcription may extend beyond the end of the
L1 element, to a downstream polyA addition signal
(Fig. 1B) [1, 13, 16, 17]. Thus the insert usually consists
of polyA, with a variable amount of upstream sequence,
which may or may not include part of the L1 sequence
itself (Fig. 1C) [18]. The inserts may also be partly
inverted, possibly as a result of priming reverse tran-
scription from both directions [19].
Paired-end sequencing is currently the method of
choice for detecting genome rearrangements in cancer
or germline DNA [20, 21]. Typically, sequence reads of
100bp are taken from both ends of genomic DNA frag-
ments of 200-500bp. The reads are then aligned to the
reference genome, allowing for some variation. Rear-
rangements are detected mainly by looking for ‘discord-
ant read pairs’, i.e. read pairs where the two reads do not
map to the same place in the genome at the expected
separation, e.g. to different chromosomes. Reads that
cross rearrangement junctions, ‘split reads’, may also be
searched for. Thus central to the analysis of the sequen-
cing data is correct interpretation of the alignment of
discordant read pairs, or ‘split reads’, to the genome.
The present study is part of a programme to sequence
the genomes of 500 oesophageal adenocarcinomas [22]
within the framework of the International Cancer Gen-
ome Consortium.
While analysing genomic rearrangements of these tu-
mours from paired-end sequencing data, we, as others
working with other tumour types [12, 13], identified a
puzzling class of genome rearrangement. Typically, sev-
eral tumours appeared to have chromosome translocation
breakpoints at the same place, to within about a kilobase,
apparently translocated to, or inserted into, many places
in the genome, in a tumour-specific way, and often with
multiple translocations in the same tumour.
We hypothesized that these ‘rearrangements’ were inser-
tions of mobile elements, detected in paired-end sequen-
cing because part of the sequence inserted was unique in
the genome.
Results
Identification of candidate mobile element transduction
events
As others have reported [12], among the rearrangement
junctions in our paired-end sequencing were groups ofapparent translocations that had highly recurrent break-
points, ‘translocated’ to many unique sites (Fig. 2). For
example, 17/22 tumours (in our discovery set Batch P)
had a total of 61 ‘translocation breakpoints’ within a
1.4kb region at 29.065 Mb (reference genome GrCH37/
hg19) on chromosome 22, within an intron of the
TTC28 gene, up to seven in the same tumour, and the
joined ‘breakpoints’ were all different. Similarly, four tu-
mours had a total of 46 junctions at 59.220 Mb on
chromosome 14 and seven tumours had a total of 29 at
11.732 Mb on chromosome X (Table 1, Additional file
1). These could be distinguished from typical artefactual
‘translocations’ resulting from misalignment of reads to
repeat sequences, because usually both ‘breakpoints’ of
such events are joined to multiple partner breakpoints.
They also did not resemble true recurrent translocations
because the breakpoints were clustered into too small a
region, generally 1kb or less. For many—typically a quar-
ter to a half—of the junctions, paired-end sequencing
detected a neighbouring junction, suggesting that the
‘translocation’ was reciprocal, perhaps with a small dupli-
cation at the breakpoint [23], or was in fact an insertion.
For example, 26 of the 61 chromosome 22 ‘translocations’
had two junctions (Additional file 1).
In the 22 tumours of Batch P, seven distinct loci had
at least five of these translocation-like junctions, spread
over more than one tumour, each breakpoint within 1kb
Table 1 ‘Elements’ in the reference genome that mobile element inserts align to
ID Chromo-some Transduced
sequence start
Transduced
sequence end
L1, Alu etc. Start End +/− Gene Total Inserts Tumours Method Max Transduced
(bp)
Hot L1
list
Tubio
list
Reference L1s that transduce unique sequence
Chr 4 chr4 137213864 in L1 L1HS 137214650 137220701 - none 3 2 L1 786 14 No
Chr 8 chr8 135082457 135082642 L1HS 135082987 135089016 - none 6 3 L1 530 3 4
Chr 12_A chr12 3606945 in L1 L1HS 3608362 3614394 - PRMT8 5 3 L1 1417 35 6
Chr 20 chr20 23412922 23413624 L1HS 23406746 23412777 + none 11 5 Cl 847 Not listed 8
Chr 22 chr22 29065365 29066424 L1HS 29059272 29065303 + TTC28 129 36 Cl, L1 1121 7 137
Chr X_A chrX 11731785 11732702 L1HS 11725369 11731399 + none 80 19 Cl, L1 1303 19 7
Chr X_B chrX 11952984 in L1 L1HS 11953208 11959433 - none 23 6 L1 224 1 20
Non - reference L1s that transduce unique sequence
Chr 3 chr3 in L1 123595443 Polymorphic L1HS 123590726 123590724 + MYLK 29 7 Cl >4000 N/A 40
Chr 14 chr14 59220410 59221078 Polymorphic L1HS 59220404 59220404 + none 179 11 Cl N/A 40
Reference genome elements that inserts align to
Chr 6 chr6 L1HS 24811907 24817934 - FAM65B 3 3 L1 Nil 2 N/A
Chr 7 chr7 L1HS plus 4bp and polyA 30478859 30484914 + NOD1 84 9 L1 Nil 18 N/A
Chr8 see footnote L1HS
Chr 10 chr10 L1HS with polyA 111572121 111578215 - none 6 6 L1 Nil 9 N/A
Chr 12_B chr12 AluSx1 with polyA 66451373 66451739 - none 98 21 Cl Nil N/A N/A
Chr 15 chr15 AluYa5 with polyA 77910868 77911236 - LINGO1 19 17 Cl Nil N/A N/A
Positions refer to reference genome GRCh37/hg19. The mobile ‘elements’ are identified by chromosome. At least two inserts were verified by PCR for each ‘element’ except the Chr 6 element (only one insert verified)
and the Chr 3 element (not verified but described by Tubio et al. [13]). The Chr 3 and Chr 14 elements are polymorphic L1s that are not in the reference genome but were shown to transduce sequence by Tubio et al.
[13]; their insertion point in the reference genome is given in italics. The polyA addition site for the Chr 14 element is at the end of a 36bp fragment of an L2a element. The Chr8 element showed both transduction
and mapping to the native L1 insert—of the two inserts verified, one had 3’ unique sequence transduced and one was pure L1 3’ terminus
Transduced sequence, maximum extent of unique sequence observed in inserts verified by PCR (Additional file 2), except for Chr 3 element where read map position is given. +/−, strand bearing polyA, which is same
as orientation of L1 or Alu if present. Tumours, number of tumours with inserts. Method, method of identification: Cl, cluster of ‘translocation’ breakpoints from discordant reads; L1, cluster of breakpoints 3’ to a known
active L1 (not exhaustive). Max transduced, maximum unique sequence transduced in cloned insert. Hot L1 list, rank in list of active L1s of Brouha et al. [24]. Tubio list, whether the elements that transduce 3’ sequence
were listed by Tubio et al. [13] and how many inserts were reported; N/A, not applicable as were not transduction events
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which were verified by PCR as described below.
We hypothesized that these were insertions of L1
mobile elements, and to explore this idea we searched
both Batch P and the 21 Batch B1 tumours for re-
arrangement junctions that mapped to, or close to, the
3’ ends of the 90 L1s in the reference genome that are
thought to be capable of mobilisation (Table four of
ref. [24]). This identified nine junction clusters, two of
which were among the seven originally identified (Table 1;
Additional file 1).
The combined list of apparent inserts was compared
to known L1, Alu and SVA polymorphisms [13, 25, 26]
and only eight (of nearly 700) ‘insert sites’ corresponded
to known polymorphisms that we had failed to sample
in the normals (Additional file 1).
Inspection of the inserts suggested two ways in which
inserts created by mobile elements could be identified as
rearrangements by conventional paired-end-read map-
ping: the first, when the inserts included unique se-
quence transduced by the mobile element, and the
second, when the insert included sequence that could
be—correctly or incorrectly—uniquely matched to a mo-
bile element in the reference genome (Fig. 1).
The first way accounted for several ‘clusters’ of inserts
that included unique sequence that mapped 3’ to the
end of an L1 in the reference genome (Table 1). The
chromosome 22 element was typical—inserts included
sequence 3’ to an L1 at chr22: 29059272–29065303, ex-
tending to at least 29066424.
Two further clusters of inserts of unique sequence—at
chromosome 3: 123.59 Mb and chromosome 14: 59.22
Mb (the most abundant in our original set)—resembled
transduced sequence but were not adjacent to L1s in the
reference genome. They were adjacent to polymorphic
L1s absent from the reference genome [26] and known
to transduce 3’ flanking sequence [12, 13] (Table 1). The
chromosome 14 element, for example, is inserted in the
reference sequence at 59220404 in 25 % of the popula-
tion sampled by Tubio et al. [13], in the plus direction.
Our inserts all ended in polyA added at map position
59221073–59221078 (Table 1).
The second way that candidate inserts were detected,
was when a cluster of breakpoints was mapped to the 3’
terminus of an L1 or Alu in the reference genome with
or without a polyA tail. Although these sequences are
‘repeats’, they are sufficiently distinct in the reference
genome that aligners (which do not mask repeat se-
quences) may align reads confidently to these positions
because they match a read better than anywhere else
(Fig. 1 D; Table 1). For example, 84 rearrangement junc-
tions, spread over nine tumours, were mapped to the 3’
end of an L1 that ends at 30,484,890 bp on chromosome 7
and is followed by a 4 bp gap then 20As.Similarly, approximately 100 junctions, in 21 tumours,
mapped to the longest polyA run in the reference gen-
ome, the 90-bp polyA tail of an Alu at chr12:66451373–
66451739, while 22 junctions in 18 tumours mapped to
the 79 bp polyA tail of an AluYa5 at chr15: 77910868–
77911236. The interpretation of these depended on the
aligner used. The Novoalign aligner (Batch B1 tumours),
which can trim reads more to achieve a match, generally
aligned reads to them solely because they contained 70 or
more polyA/T, without Alu sequence, but with or without
a few bp 3’ to the polyA that may represent common tar-
get site sequence. For example, the read TTATTC[74
polyT]GGGAGAGAGATTTTTTTTTT was aligned to
the chromosome 15 locus by matching the TTATTC and
polyT, then trimming off the remaining base pairs. Of
three tested by PCR for each locus (see below; Additional
file 2), all were somatic inserts. Two were essentially only
polyA while four included an L1Hs 3’ terminus ignored by
the aligner.
The aligner BWA (Batch P tumours) aligned reads to
these polyA runs by matching polyA plus some recognis-
able Alu sequence. Their apparent insertion sites were 3’
to reference Alu sequences, and two—at about 49.3603
Mb on chromosome 19 and 141.014 Mb on chromosome
2—were common to two tumours, so these may represent
germline polymorphisms of longer polyA tails on these
reference Alus that we failed to sample in the matched
normals and normal panel.
Thus this second class of apparent rearrangements are
where an aligner confidently maps reads to the 3’ end or
polyA of a mobile element in the reference genome.
These may occasionally represent mobilisations of that
reference mobile element, but more commonly will be
incorrect mappings of an insert from an unrelated elem-
ent, or a polymorphism.
A third class of apparent junction, observed only using
the Novoalign aligner, appeared to be a special case of
such mismappings, which we designated ‘split mappings’.
Apparently, reads from within one mobile element in-
sert were mapped to different places in the reference
genome (Fig. 1E). For example, we identified a ‘transloca-
tion junction’ between chromosome 14:59.2206 Mb,
which is sequence transduced by an L1, and the polyA run
at chromosome 15:77.9109 Mb (Table 1). Presumably the
sequence reads are from an insert of the chromosome
14 L1 that has transduced flanking sequence, and its
added polyA tail. We detected ‘junctions’ of this kind
that mapped to the chromosome 14 and X_A transduced
sequences at one end and either the chromosome 12 or
15 polyA runs at the other. Four other junctions ap-
peared similar, joining the chromosome 14 or 15 loci
either to an L1Hs at chr2:88206897–88206997 or se-
quences found to be transduced by Tubio et al. [13]
(Additional file 1).
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Using PCR, we verified that rearrangement junctions
existed and were somatic for at least two inserts from
each element in Table 1, except the chr3 element (not
attempted) and chr6 (only one attempted). Inserts with
read pairs at both ends were preferred (Additional file 1)
(this would bias towards truncated inserts, see Fig. 1).
For 25/45 inserts we were able to amplify across the in-
sert, using primers designed to the expected flanking se-
quence (Fig. 3A; Additional file 2). For a further 17, we
were able to amplify across at least one junction, giving an
overall verification rate of 42/45 tumour inserts (93 %).
Failure to amplify some junctions and inserts is not sur-
prising, since some inserts would be too large to amplify
and many primers were designed by guessing the other
side of an insert, which could have been rearranged or de-
leted [1]. All inserts were tumour-specific. Amplifying
across the inserts gave a product from the normal target
site, common to the tumour and matched normal, plus a
larger band unique to the tumour. In addition, a weaker
intermediate band was often obtained, which on cloning
and sequencing gave sequence the same as the normal or
insert band and therefore we suspected was a hybrid be-
tween the normal and insert bands. Supporting this inter-
pretation, when excised and re-run, the normal and larger
insert bands ran as expected, while the intermediate band
regenerated the pattern of three bands.Fig. 3 Verification of representative inserts. a Flanking junctions of an inser
b PCR across four representative inserts, of elements denoted Chr X_B, Chr
tumour-specific band in most cases there is an intermediate size band, mo
site duplication (TSD), insert of chromosome 22 material and polyA tailAll verified inserts had the expected structure, allow-
ing for known variations. All had a polyA tail, with up-
stream insert sequence variably truncated (Fig. 3;
Additional file 2). Most were flanked by target site dupli-
cation, up to 20bp, as expected [10, 13], though some in-
serts showed zero duplication or even a small deletion
(Additional file 2). Variations included partial inversion
of the 5’ end of the inserted sequence—about 20 % (36/
195) of inserts where both ends were found by discord-
ant read analysis. For example, the insert shown in Fig. 3,
of chr22 into chr 8 consisted principally of chr22 se-
quence, from 29066229–29066424, 3’ to the intact L1
that ends at 29065303, followed by 37bp of polyA
(Fig. 3). There was an apparent small inversion at the 5’
end, with the first 17 bp of the insert mapping in the re-
verse orientation 54 bp upstream to the main chr22 ma-
terial, consistent with the proposed mechanism for
inversion [19]. The insert was flanked by an 18-bp target
site duplication.
The inserts we verified and sequenced across ranged
from 1bp (plus >50 polyA and target site duplication) to
about 1kb excluding the polyA, and the polyA sequences
ranged from roughly 25 to over 50 (polymerase slippage
means that these figures are approximate). The inserts
of transduced 3’ unique sequence included part or all of
the transduced unique sequence, with or without part of
the upstream L1HS sequence. For example, the insertt from chromosome 22 into ENPP2 on chromosome 8 in Tumour 7396.
6, Chr 7 and Chr 14 respectively. Note that in addition to the larger,
st clearly in the last example. c sequence of insert in a, showing target
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the insert of the chr4 element into chr5 included 69bp
of the 3’ end of the (negative-strand) L1HS together with
931bp of unique chromosome 4 material downstream of
this end.
The sequences transduced 3’ to intact L1s mostly were
bounded by polyA addition sites 0.8-1.3 kb from the L1,
though one, from the element at 119.5 Mb on chromosome
X, extended only 24bp from the L1. For some the polyA
addition sites varied, e.g. for the chromosome 22 element,
the L1 of which ends at 29,065,303, there were two cases of
polyA addition at 29,065,912, two at 29,066,121, one at
29,066,424, and others. The chr8 element was found both
with 3’ unique sequence transduced and without any trans-
duced sequence.
Estimating abundance of inserts by detecting polyA
Since the total number of L1–mediated insertions is
likely to be much greater than detected by discordant
read pairs, which only works where reads in the insert
can be mapped uniquely to the reference genome, we
obtained a rough estimate of total inserts by searching
for tumour-specific polyA sequence, hypothesising that
most of these would be L1-mediated insertion events.
We searched the 43 tumours of sets P and B1 for
reads that contained at least 20 consecutive As or Ts
and were paired with sequence reads that were confi-
dently mapped by the BWA aligner. From these we ex-
tracted candidate inserts that were supported by at least
three read pairs and absent not only from the matched
normal but also the 20 or 21 other normals from the
same batch of tumours (Additional file 3). We compared
these candidate insert sites to known polymorphic L1s
and Alus [13, 25, 26], and about 1 % (63 out of approxi-
mately 5300) were within 1kb, without considering dir-
ection of read. As a control, the analysis was repeated
with each B1 tumour interchanged with its matched
normal: this detected only an average of 2 (range 0 to 6)
candidate normal-specific polyA sequence runs (1/42 of
which matched a known polymorphism), suggesting that
relatively few of the inserts detected in the tumours were
merely bioinformatic artefacts or polymorphisms that
we had failed to detect in the matched sample.
We confirmed that the great majority of these candi-
date insertions resembled tumour-specific L1 events, by
manually scrutinizing a random sample of 20 of the
least-confident examples, i.e. those supported by only
three reads. We viewed all sequence reads within an ap-
proximately 600bp window spanning the candidate in-
sert site, using the Integrative Genomics Viewer (IGV)
[27] (Additional file 4). All 20 showed additional aber-
rant reads including additional ‘split’ or ‘soft-clipped’
reads (i.e. reads partially aligned to the reference with a
‘tail’ of mismatched bases) that clearly identified aninsertion point. In 18/20 cases these split reads included
L1 sequence. In one further case the sequence appeared
to be transduced. In only 1/20 cases was the insert
clearly germline, while only one further case had a single
read in the normal that could possibly have supported a
germline insert (Additional file 4).
For around 85 % of an independent unbiased sample of
the candidate tumour-specific polyA sequence we were
able to verify a retrotransposon insert by PCR across the
candidate insert site, and some of the failures might have
been inserts that were too large to amplify (Additional file
2). 28 primer pairs were designed, of which 26 pairs suc-
cessfully amplified a normal band from the matched nor-
mal. 22 of these 26 (85 %) amplified a larger band from
the tumour. All these insert bands were absent from the
matched normal. 11 of these 22 were cloned and se-
quenced. All showed an insert that included polyA, to-
gether with additional sequence (Additional file 2). 10/11
had target site duplication, suggesting they were indeed
non-LTR retrotransposon events. 8/11 included the 3’ end
of L1HS sequence, for example, the largest was 7416_19,
almost 600bp, comprising around 450 bp of L1 sequence,
slightly rearranged, with two stretches of polyA separated
by a 75bp fragment of chromosome 9, flanked by duplica-
tion of TAGAAGCCCAATTTCT. The three without L1
sequence included the smallest, 7436_9, which was ATA-
TAATAATAAT + polyA, flanked both sides by CCCA,
which is a duplication of the native chromosome 9 target
site. ATATAATAATAAT does not match the end of a con-
sensus L1HS or Alu. Insert 7416_13 comprised 67 bp unique
sequence from chromosome 10:120,819,239-120,819,305,
plus polyA and duplication of AAGAAATATTTCCC.
Insert 7416_10 was about 1kb of unique sequence from
chromosome 17 chr17:46707420–46708467, inserted with
a target site duplication of 14bp, but with polyA at both
ends, A31 and A16 allowing for the original sequence, in
the same orientation. Neither of these two are near refer-
ence L1s or known polymorphic L1s [13, 25, 26]. They
might represent undocumented polymorphic L1s or re-
mobilisation of somatic inserts [13], and, indeed, dis-
cordant read pairs show nine rearrangement breakpoints
within chr17:46707414–46708480 in tumour 7416, indi-
cating multiple transductions of this sequence.
A further four inserts were also verified, three chosen
because they were in genes, PARK2, FOXP2 and SNTG
(Additional file 2).
Taking 85 % as an estimate of validity, our rough esti-
mate of tumour-specific inserts identified by polyA se-
quence ranged from five (which may be artefactual
background) to about 700, average approximately 100
(Table 2). This is over six times the number of inserts
from the elements listed in Table 1 detected as re-
arrangement junctions. This may be an underestimate
because read pairs have to be placed precisely to detect
Table 2 Active elements in individual tumours
Tumour Element Elements
active
Inserts by
discordant reads
Candidate
Poly A inserts
TP53
Mutation3 4 8 12_A 14 20 22 X_A X_B ?
3109 3 1 26 1 1 5 32 150 MUT
3111† 1 1 1 96 MUT
3113 2 2 2 3 6 13 MUT
3115 3 1 2 4 33 MUT
3117 0 0 10 MUT
3119 0 0 8 —
3121 4 3 1 3 8 34 MUT
3125 0 0 7 —
3129 6 1 6 129 MUT
3131 1 1 2 2 12 MUT
3133 1 1 2 2 11 —
3135 6 1 2 7 16 MUT
3137 1 1 1 5 MUT
3149 5 3 7 3 15 19 MUT
3302 9 8 3 21 4 41 389 MUT
3305 5 2 2 7 16 MUT
3308 6 8 2 14 194 MUT
3311 1 5 1 3 7 95 MUT
3314 4 1 2 5 22 MUT
3317 14 4 1 3 19 70 MUT
3320 2 4 2 3 8 97 MUT
3323 3 1 2 4 27 MUT
7394 4 2 7 14 4 27 281 MUT
7396 2 10 8 35 4 55 830 MUT
7398 2 12 4 6 11 5 35 231 MUT
7401 1 2 2 2 1 3 6 11 138 MUT
7404† 2 1 2 13 MUT
7407 22 1 7 3 4 33 196 MUT
7409 85 3 10 1 15 35 6 149 416 MUT
7414 1 1 3 3 5 33 MUT
7416 0 4 11 2 15 196 MUT
7418 4 3 2 3 9 73 MUT
7420 1 2 6 2 1 1 6 13 100 MUT
7422 1 1 1 4 4 7 62 —
7424 8 2 5 32 4 47 352 MUT
7427 2 1 2 3 5 133 MUT
7430 1 5 2 3 8 30 MUT
7432 8 3 10 3 21 133 MUT
7434 3 2 2 3 7 125 MUT
7436 3 2 1 3 6 39 MUT
7438 2 2 1 3 5 64 MUT
7440 1 5 4 3 4 13 174 —
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Table 2 Active elements in individual tumours (Continued)
7442 2 8 3 3 13 198 MUT
Total tumours 7 2 3 3 11 5 36 19 6 31
Total inserts 29 3 6 5 179 11 129 80 23 210 675 5270
Average per tumour 16 123
The elements that transduce unique sequence are listed individually, while all inserts mapped to L1s or polyA in the genome are combined in column marked ‘?’,
because it is not certain that they were copied from any specific L1. Elements active, number of different elements active in a given tumour. Inserts by discordant
reads, total inserts found from discordant paired reads. PolyA, candidate inserts found by searching for tumour-specific polyA. TP53 mutation, mutations in TP53
called from Illumina sequencing. MUT, mutated; −, no mutation detected. † Note that tumours 3111 and 7404 had verified tumour-specific inserts of the chr12_A
element, so definitely had some mobile-element activity
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enough with normal cells to reduce sensitivity of detection.
Combining the inserts found by discordant read pairs
and our polyA search (Table 2), most of the tumours
have evidence of somatic mobile element activity. Only
10/43 (23 %) tumours did not have either five or more
inserts detected by discordant pairs or >50 candidate in-
serts detected by polyA (Table 2), and one of these
(7404) had a verified insert (Additional file 2). On the
other hand, there are a few tumours that may well not
have activity, notably the 4/43 tumours that have zero or
one unverified insert detected by discordant reads.
Effects on genes
Among the inserts found by analysing discordant reads
pairs, 198/675 (29 %) were in a gene listed by Ensembl.
Of these, approximately 90 were in the same transcrip-
tion direction as the gene, 108 in the opposite orienta-
tion. (These are approximate figures because only one
junction was detected in most cases, and the orientation
of this junction could be misleading in cases with 5’
inversion).
Five inserts seemed particularly likely to affect gene
function: four were in coding sequence, of MRPL13 and
ZAN (both confirmed by PCR), SYCP1 and ZDHHC14;
and one was in the 3’ UTR of PDE10A (confirmed).
Several genes had inserts in more than one tumour
(not confirmed by PCR): AGBL4, DLG2 and SNTG1 had
insertions in three tumours; AGBL1, AREG, EDIL3,
EPHA6, GPM6A, LRP1B, NEGR1, NRXN3, PGCP, and
PLAKHA4 had insertions in two tumours. AGBL4,
ROBO2, EYS and RYR3 appeared to have two insertions
in distinct sites in the same tumour, though these could
be insertions at a single rearrangement junction, since
this is known to occur [28].
Among the insertions detected by polyA search
(Additional file 3), which are less reliable and may be
too small to affect gene function, a number of genes
had inserts in several tumours, but these were very
large genes (0.8 - 2.2 Mb) such as LSAMP, so the sig-
nificance is unclear (Additional file 3).Discussion
Mobile elements found
Our search for novel polyA sequence showed that retro-
transposition occurs in the majority of oesophageal
adenocarcinomas—40/43 had 10 or more candidate in-
sertions (Table 2)—and the number of novel inserts,
though very variable, was often in the hundreds accord-
ing to the search for tumour-specific polyA runs.
Mobile element activity has previously been explored
in several cancer types, by various methods. Some relied
on L1 sequence to permit single-ended PCR of junctions
or capture of junction fragments by hybridization [7, 9,
10]; others have used Illumina whole genome sequen-
cing and bioinformatic tools such as TEA and Transpo-
Seq (which rely on presence of L1 sequence) [8, 14]
and TraFiC (which also detects transductions that lack
L1 sequence) [13] to identify likely L1 insertion and
transduction [12] events; while Rodic et al. [29] used
staining with well-validated polyclonal and monoclonal
anti-LINE-1 ORF1p protein on tissue microarrays to
detect ongoing L1 activity. Together these suggest that
carcinomas have more L1 activity than non-epithelial
cancers, with more than half of cases having detectable
ORF1p protein and detectable inserts. Among carcin-
omas surveyed, lung NSCLC, head-and-neck squamous
and colorectal had relatively more inserts identified
than breast and prostate [7, 8, 10, 12–14] (though most
breast cases stained for ORF1p protein [29]) . The high
variability between cases of a carcinoma was illustrated
by Lee et al. [8] who detected 2 to 15 inserts in 4 of 5
colorectal cancers but 106 in the remaining case, which
also showed hypermutation and high CpG island methyla-
tion (CIMP-high).
Allowing for differences in approach, our results
(Table 2) are consistent with these surveys, and probably
place oesophageal adenocarcinomas among the tumour
types with more frequent and abundant inserts, such as
colorectal and lung cancers. TraFiC [13] detected 0 to
565 inserts in 36 lung cancers, with 4 having 187 or
more, and 75 % of patients with at least some; while 15
colorectal cancers had 0–66 inserts, with only one tumour
negative.
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has the advantage of high sensitivity but might be less
robust than more stringent approaches. However, PCR
across the candidate insert sites—which would fail for
larger inserts and so underestimates our accuracy—suc-
ceeded in amplifying an insert with retrotransposon-like
characteristics in about 85 % of cases, and manual cur-
ation of reads from 20 low-confidence examples showed
that all had additional split reads that supported the
presence of an insert. We might have expected occa-
sional inserts to be polymorphisms overlooked in the
matched normal, but all that amplified in our unbiased
sample were unique to the tumour, only about 1 % were
found among known polymorphisms [13, 25, 26], and
only one or possibly 2 of 20 manually curated examples
had any evidence they were germline.
The mobile element inserts we identified had the ex-
pected structure, allowing for known variations such as
inversion of the 5’ end, as explored in more detail by
others [8, 10, 13]. Among the less familiar variations,
one of the inserts found in our polyA search, 7416_10,
had polyA at both ends. Extreme examples of truncation
were found, including one insert of polyA plus 1bp and
target duplication (insert mapped to chr15 locus, inserted
into chromosome 16; Additional file 2).
As expected, all the intact L1s implicated in formation
of our inserts were from family L1HS, the human-
specific L1 family, thought to be the only currently-
active L1s. Most were in the original list of active ‘hot
L1s’ prepared by Brouha et al. [24], based on December
2001 genome data plus functional assay of the L1’s activ-
ity in vitro. Our list includes their three most active L1s
and eight of our list are in their top 20. However, this is
biased by our use of the hot L1s to find examples. One
of our original three active L1s identified purely from
read pairs, on chromosome 20, was not listed by Brouha
et al. [24], but matches their consensus sequence 99.6 %.
Two of the most active elements, the Chr 3 and Chr 14
elements, are L1s absent from the reference but present
respectively in 77 % and 25 % of cases examined by
Tubio et al. [13].
We did not find positive evidence of Alu mobilisation.
Although we found discordant reads aligned adjacent to
Alus on chromosome 12 and 15, these alignments were
essentially to their polyA tails, as discussed below.
Why are the transduced sequences unique?
A puzzling feature of the 3’ transduction events is that
the sequence transduced is unique in the reference gen-
ome. This is paradoxical since, if the mobile element
were active in the germline, there should be multiple
copies in the reference genome. It follows that there
may be 3’ transduced sequences that are not unique in
the genome because they have already been copied. LikeL1s, new inserts of these sequences will not be mapped
by aligners and so will usually go undetected.
Activation of multiple elements
As also noted by others [13, 14], the 3’ transduction
events, which identify the L1 that gave rise to the insert
(Table 2) show that, where inserts were detected in a
tumour, several elements were often mobile, rather than
individual elements becoming active singly (Table 2).
However, two of the three tumours with 12_A inserts
had no other junctions detected, and the relative num-
ber of inserts of elements 22 and X_A varied from 6:0 in
tumours 3129 and 3135, to 1:5 in tumour 7440, suggesting
some differential activation, unless detection is skewed by
technical details such as the aligner used, different frag-
ment size and effective coverage in sequencing of the two
tumour batches. Differences in activity of the chromosome
3 and 14 elements are of course partly determined by
whether or not the individual has the element.
Activation and genetic instability
An interesting corollary is that activation of these ele-
ments might constitute a new type of genetic instability
in cancer. However, we cannot say whether L1s are spe-
cifically activated in these tumours or are also active in
normal cells, because the non-cancer cells may be too
polyclonal for new inserts to be detected. Also, even if
activation is cancer-specific, it is not necessarily a dis-
tinct genetic instability phenotype: in particular, p53/
TP53 mutation may be permissive for cells to survive ac-
tivation of retrotransposons [29, 30], and activation may
be just one consequence of p53 loss. Almost all these
Oesophageal adenocarcinomas are p53 mutant (Table 2;
[22, 31]), and two (3119 and 3125) of the three tumours
where no insertions were detected by discordant reads
were two of the five tumours with no detected p53 mu-
tation (Table 2).
Do the inserts mutate genes?
Mobile element insertions can alter genes in various ways
[1]. Apart from direct insertion into exons—as in the APC
gene in a colon cancer [6]—they can terminate transcrip-
tion by providing a polyA addition site, either the site used
in creating the insert mRNA or, when in reverse orienta-
tion, an antisense polyA addition site about 0.5 kb from
the 3’ end of the consensus L1 sequence [32]. But the 5’
UTR can also activate expression, in either orientation,
since it includes a potent antisense promoter.
Some of our inserts might be in driver genes. The in-
sert shown in Fig. 3 is in ENPP2, which is a nucleotide
phosphodiesterase and phospholipase. It is fused in the
breast cancer cell line ZR-75-30 [33] and may be upreg-
ulated in cancers. Of the genes listed in Results—with
inserts in exons or almost in exons, or with multiple
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and is a target of insertions in colon tumours [10].
Among the genes with single inserts in introns, de-
tected by discordant read pairs, are several identified
elsewhere as likely drivers: CNBD1 reaches driver status
in exonic mutations [35], while RSPO2 is a known onco-
gene [36]. Tubio et al. [13] recorded an insert in CNBD1
also. CNTNAP5 was highlighted as relatively frequently
mutated in exome sequencing of oesophageal adenocar-
cinoma [22, 31].
Activation of genes by inserts may be important.
Davoli et al. [37] analysed reported patterns of mutation
to identify likely tumour suppressors and oncogenes. We
found many inserts in genes scored with moderate confi-
dence (score 3 out of 4) as oncogenes—COL22A1,
CSMD3, GaBRG2, PGM5, RALYL, RGS22, RSRC1, and
TRPS1—while no inserts were in candidate tumour sup-
pressors at confidence 3 or 4. Several of these genes and
SYCP1, mentioned above, are involved in gene fusions:
RGS22, SYCP1 and TRPS1 in breast cancer cell lines
[33, 38], and RSPO2 in colon cancers [39]. This hints at
insertional activation.
How inserts are detected by paired-end analysis
We classified the inserts we found based on how they
were identified by aligning sequences to the reference
genome (Table 1). Most current strategies for analysis of
structural variation in the genome by paired-end se-
quencing, as generated by the Illumina technology, rely
on matching sequences to the reference genome, then
looking for such abnormalities as ‘discordant read pairs’
where the reads map an abnormal distance apart, e.g. to
different chromosomes; or ‘split reads’, where different
parts of the same individual sequence read map to dif-
ferent locations in the genome [20].
Mobile element insertions give a variety of unexpected
behaviours in such analysis. The first class of inserts we
identified were inserts that include unique sequence lo-
cated 3’ to L1s and had been transduced: these inserts
appear to be junctions between the unique sequence and
somewhere else in the genome. Many of the inserts ap-
pear to be translocations because the other end of the
insert is repeat sequence, and therefore is not identified
by discordant reads. We identified nine L1HS elements
that transduce sequence this way, eight of which have
been recorded by Tubio et al. [13], who described a total
of 72. These inserts subdivide according to whether the
L1 is in the reference genome or not (Table 1). Many re-
cent L1 insertions in the germline are active, and are
polymorphic and absent from the reference genome [13,
25, 26, 40]. Transduction by non-reference L1s is more
difficult to identify because it requires a list of all active
polymorphic L1s or a search of the matched normal
genome for L1s. Our two examples—the chr 3 and chr14 elements—were only detected by us because they are
present in many individuals and very active, so produced
large numbers of apparent breakpoints within a kilobase
or so.
The second major class of inserts detected by discord-
ant read pairs were inserts that the aligner software
could map uniquely to a mobile element or its associ-
ated polyA, in the reference genome. These also resem-
bled translocations to, or insertions of, the reference
element. The inserts did not necessarily come from that
element, because the alignments may have depended on
the presence of polyA. Most striking were the chromo-
some 12 and chromosome 15 ‘elements’, which are the
longest and third-longest polyA runs in the reference
genome. The Novoalign aligner, which has enhanced abil-
ity to trim reads to obtain a match, confidently mapped
reads here merely because they contained a long polyA
string. In raw sequence alignments we also found reads
aligned to the second-longest polyA run, 83bp at
chr6:160521756–160521835, but only one junction with
this mapping was unique to a tumour and so appeared
as a candidate junction.
Finally, some apparent ‘translocation junctions’ were
not even junctions, but occurred when read pairs within
a mobile element insert were mapped to two distinct loci
(Fig. 1E). Typically, one read of a pair was in transduced
sequence, the other was in the polyA tail and mapped to
one of the long polyA runs in the reference.
Consequences for paired-end sequencing
Our data highlight difficulties and pitfalls in identifying
mobile element insertions in paired-end sequencing
data, and in distinguishing them from genomic rear-
rangements, some of which have already been flagged by
Pitkänen et al. [12] and Tubio et al. [13].
Searches for mobile element inserts will have to allow
for truncation and transduction, which result in inserts
that may have little or no sequence from the mobile
element proper [13, 18]. Of our 15 sequenced polyA in-
serts, all but one had target site duplications, as expected
of non-LTR retrotransposons, but only 11/15 had L1 se-
quence in the insert, while the other 4 had unique sequence
or a fragment that was unrelated to L1 and too small to
map. TraFiC [13] attempts to address this problem.
It will also be difficult to achieve high sensitivity. To
identify inserts from discordant reads, the reads have to
fall in exactly the right places (Fig. 1), reducing effective
coverage, and many inserts are too small to accommodate
a whole read—of the 15 polyA inserts we sequenced, four
were smaller than 100bp excluding the polyA, and one
was only 13bp + 49 As. Split read analysis will help
(Additional file 4), but may introduce additional artefacts
such as ‘split mappings’ (Fig. 1E). It may be helpful to flag
and isolate runs of polyA as a specific feature of reads.
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ing structural rearrangements of the genome. Inserts
maybe misidentified as translocations [12]. For some in-
serts, junctions will be found at both ends, but these are
still indistinguishable from reciprocal translocations, es-
pecially since translocations may have duplication or de-
letion at the breakpoints [23]. Often there is no sign that
the insert is an insert, because the junction 5’ relative to
the mRNA intermediate is not unique and so not de-
tected. Cataloguing transducable sequences will help,
but since some somatically acquired L1 insertions can
go on to generate new insertions [13], such catalogues
will never be exhaustive. Again, searches for novel polyA
may help.
Finally, our results illustrate that different aligners will
produce different artefacts.Conclusions
New mobile element insertions are abundant in oesophageal
adenocarcinomas. Since inserts may inactivate or activate
genes, they are likely to contribute to mutation burden.
The inserts create a variety of problems for the interpret-
ation of paired-end sequencing as currently performed.
Many element insertions will be missed in searches for
L1s, because they are truncated and carry little or no L1
sequence. Conventional searches for structural rearrange-
ments of the genome will miss inserts because their ends
consist of repeat sequences and polyA, which cannot be
mapped to the reference genome by aligner software. Even
those that that are detected may resemble structural vari-
ants, and they may be difficult to identify with mobile
element activity because the insert will not always contain
retrotransposon sequence [18].Methods
Tumours and cell lines
Batch P (numbered 3108–3323) were the 22 discovery
cohort oesophageal adenocarcinomas with matched nor-
mal squamous epithelium or blood as described [22].
Batch B1 (7394–7442) were a further 21 tumours all
with matched blood (Additional file 5). Briefly, the tu-
mours reflected the known clinico-demographic features
of the disease: male predominance (6:1), mean age 68
years (53 to 82), and mostly advanced disease (33/43 >
stage I). The study was approved by the East of England-
Cambridge South National Research and Ethics Service
Committee (Research Ethics Committee Numbers 10/
H0305/1 approved 17/02/2010 and 07/H0305/52 ap-
proved 28/08/2007), and all patients gave individual in-
formed consent. Sample collection and DNA extraction
were as described [22]. Authenticated Oesophageal
adenocarcinoma cell lines [41] OE33, JH-EsoAd1 and
FLO-1 were obtained from the originators or EuropeanCollection of Cell Cultures (ECACC) (OE33), and iden-
tity checked by short tandem repeat (STR) analysis.
Paired-end sequencing
100bp paired-end sequencing was performed, on a single
library per sample, under contract by Illumina on the
Hi-Seq-2000 (Illumina, San Diego, CA) to a depth of at
least 50x. Two protocols were used: Batch P and matched
normals were sequenced to a mean coverage of 63-fold,
using a PCR-amplified library of gel-purified fragments of
median size 277-367bp, median absolute deviation 15 –
46. Some of these libraries contained large numbers of ap-
parent small inversions, possibly caused by circularisation
of fragments with single-stranded ends during library
preparation, so inversions of less than 10kb were dis-
carded. Occasional read pairs differed from another read
pair by only one or two basepairs at one end, presumably
PCR duplicates where a sequencing primer had lacked
a terminal base [33, 42]. Batch B1 tumours were se-
quenced using TruSeq DNA PCR-Free protocol, giving
median fragment sizes of 290–343, median absolute de-
viation 60 – 75. Few if any artefactual small inversions
were present and no imperfect PCR duplicates. Sequen-
cing of the cell lines was performed under contract by
Beijing Genomics Institute similarly to batch P, with in-
sert size around 500bp.
After quality control [22], read sequences were aligned to
human reference genome GRCh37/hg19 using Burrows-
Wheeler Alignment (BWA) [43], exact PCR duplicates re-
moved using Picard [44]. For Batch B1 only, reads that did
not map normally were re-aligned with Novoalign (Novo-
craft Technologies, Selangor, Malaysia). Rearrangements
(structural variants) were identified from discordant read
pairs, i.e. read pairs that failed to map to the reference
genome at the expected separation and orientation [20],
essentially as described [33, 45]. Discordant reads were
sorted into clusters then separated into subclusters that
supported the same rearrangement junction. For Batch P,
we required rearrangements to be supported by at least
three read pairs in the tumour, but without any read pairs
in either the matched normal or any other normal from
the same batch, i.e. 19 or 20 additional normals. For Batch
B, with fewer known library artefacts, we also accepted re-
arrangements supported by only two reads. Around 10 %
of rearrangement junctions were discarded because there
was a plausible normal alignment of the pair of read clus-
ters (90 % identity between mapped position and expected
normal location, over at least 100 bp).
The polyA search identified sequence reads that con-
tained 20 consecutive As or Ts and were paired with
reads that had been confidently mapped by the BWA
aligner (without Novoalign), mapping quality ≥30. Se-
quences were discarded if ≥80 consecutive bases had the
lowest base quality score (marked ‘#’ in the BWA output),
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ence genome within 500bp of the mapped position (<10 %
for most tumours).
Verification
PCR primers (Additional file 2) were designed for an-
nealing temperatures of 59 to 66°C. PCR products ob-
tained from amplification of whole inserts were cloned
and plasmids sequenced by Sanger sequencing. Products
from individual junctions were sequenced directly.
Where PCRs failed new primers were designed. Putative
inserts discovered by discordant read pairs were sampled
for verification first from tumour 3320, then choosing
examples from tumours for which we already had DNA
readily available. Inserts with reads at both ends were
preferentially sampled. To sample polyA inserts for veri-
fication in an unbiased way, an insert was chosen that
was nearest to each 100 Mb interval along the genome,
taking different tumours, two of high and two of low
cellularity, as judged by the size of copy number steps.
This sampling preceded the comparison with known
polymorphisms.
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